Notably, all mice in the anti-PD-1/TMZ combined therapy group were declared cured, i.e., all tumours were reduced to a stable tissue scar for one month and the mice were re-challenged (see Section 2.4). This evidence concerns the gene PDCD1 and neoplasm.